These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 21285460)

  • 1. Using the Mehran risk scoring tool to predict risk for contrast medium-induced nephropathy in patients undergoing percutaneous angiography.
    Raingruber B; Kirkland-Walsh H; Chahon N; Kellermann M
    Crit Care Nurse; 2011 Feb; 31(1):e17-22. PubMed ID: 21285460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statins for prevention of contrast-induced nephropathy in patients undergoing non-emergent percutaneous coronary intervention.
    Kandula P; Shah R; Singh N; Markwell SJ; Bhensdadia N; Navaneethan SD
    Nephrology (Carlton); 2010 Mar; 15(2):165-70. PubMed ID: 20470274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contrast medium dose-to-GFR ratio: a measure of systemic exposure to predict contrast-induced nephropathy after percutaneous coronary intervention.
    Nyman U; Björk J; Aspelin P; Marenzi G
    Acta Radiol; 2008 Jul; 49(6):658-67. PubMed ID: 18568558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contrast nephropathy in high-risk patients undergoing coronary angiography and intervention.
    Uddin MA; Rabbani MA; Jafary FH; Bhatti MA; Islam M
    J Coll Physicians Surg Pak; 2005 Dec; 15(12):791-4. PubMed ID: 16398973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Forced euvolemic diuresis with mannitol and furosemide for prevention of contrast-induced nephropathy in patients with CKD undergoing coronary angiography: a randomized controlled trial.
    Majumdar SR; Kjellstrand CM; Tymchak WJ; Hervas-Malo M; Taylor DA; Teo KK
    Am J Kidney Dis; 2009 Oct; 54(4):602-9. PubMed ID: 19535188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequency and predictors of contrast-induced nephropathy after angioplasty for chronic total occlusions.
    Aguiar-Souto P; Ferrante G; Del Furia F; Barlis P; Khurana R; Di Mario C
    Int J Cardiol; 2010 Feb; 139(1):68-74. PubMed ID: 19056138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-coronarography application of continuous veno-venous hemofiltration in the prevention of contrast nephropathy in patients with complex multisystem deficiency.
    La Manna G; Pancaldi L; Dalmastri V; Cuna V; Capecchi A; Comai G; Persici E; Bacchi G; Cianciolo G; Lombardi A; Marrozzini C; Colì L; Stefoni S
    In Vivo; 2008; 22(1):123-9. PubMed ID: 18396794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of fenoldopam to prevent radiocontrast nephropathy in high-risk patients.
    Madyoon H; Croushore L; Weaver D; Mathur V
    Catheter Cardiovasc Interv; 2001 Jul; 53(3):341-5. PubMed ID: 11458411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography.
    Oldemeyer JB; Biddle WP; Wurdeman RL; Mooss AN; Cichowski E; Hilleman DE
    Am Heart J; 2003 Dec; 146(6):E23. PubMed ID: 14661012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of contrast-induced nephropathy in diabetic patients undergoing elective cardiac catheterization or PCI: role of volume-to-creatinine clearance ratio and iodine dose-to-creatinine clearance ratio.
    Worasuwannarak S; Pornratanarangsi S
    J Med Assoc Thai; 2010 Jan; 93 Suppl 1():S29-34. PubMed ID: 20364554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum antioxidant capacity and the risk of contrast medium nephropathy.
    Elias M; Swae'ed S; Shneor A; Turgman Y; Saliba W; Goldstein LH; Rosenfeld T
    Nephron Clin Pract; 2005; 99(1):c13-7. PubMed ID: 15637458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of NaCl saline hydration and N-Acetyl Cysteine to prevent contrast induced nephropathy in different populations of patients at high and low risk undergoing coronary artery angiography.
    Calabrò P; Bianchi R; Caprile M; Sordelli C; Cappelli Bigazzi M; Palmieri R; Gigantino G; Limongelli G; Capozzi G; Cuomo S; Calabrò R
    Minerva Cardioangiol; 2010 Feb; 58(1):35-40. PubMed ID: 20145594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium bicarbonate, N-acetylcysteine, and saline for prevention of radiocontrast-induced nephropathy. A comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedures. A single-center prospective controlled trial.
    Ozcan EE; Guneri S; Akdeniz B; Akyildiz IZ; Senaslan O; Baris N; Aslan O; Badak O
    Am Heart J; 2007 Sep; 154(3):539-44. PubMed ID: 17719303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reno-protective effect of N-acetyl cysteine in patients with impaired renal function undergoing coronary angiography and interventions.
    Ramesh N; Pillai RK; Abraham T; Padmaja NP; Hameed S; Vijayaraghavan G
    J Assoc Physicians India; 2006 Jun; 54():449-52. PubMed ID: 16909692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reducing the delay in thrombolysis: is it necessary to await the results of renal function tests before computed tomography perfusion and angiography in patients with code stroke?
    Mehdiratta M; Schlaug G; Kumar S; Caplan LR; Selim M
    J Stroke Cerebrovasc Dis; 2008 Sep; 17(5):273-5. PubMed ID: 18755406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of high-dose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. The LIPSIA-N-ACC (Prospective, Single-Blind, Placebo-Controlled, Randomized Leipzig Immediate PercutaneouS Coronary Intervention Acute Myocardial Infarction N-ACC) Trial.
    Thiele H; Hildebrand L; Schirdewahn C; Eitel I; Adams V; Fuernau G; Erbs S; Linke A; Diederich KW; Nowak M; Desch S; Gutberlet M; Schuler G
    J Am Coll Cardiol; 2010 May; 55(20):2201-9. PubMed ID: 20466200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of cardiac angiography timing, contrast media dose, and preoperative renal function on acute renal failure after coronary artery bypass grafting.
    Medalion B; Cohen H; Assali A; Vaknin Assa H; Farkash A; Snir E; Sharoni E; Biderman P; Milo G; Battler A; Kornowski R; Porat E
    J Thorac Cardiovasc Surg; 2010 Jun; 139(6):1539-44. PubMed ID: 19969314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease.
    Toso A; Maioli M; Leoncini M; Gallopin M; Tedeschi D; Micheletti C; Manzone C; Amato M; Bellandi F
    Am J Cardiol; 2010 Feb; 105(3):288-92. PubMed ID: 20102936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification.
    Bartholomew BA; Harjai KJ; Dukkipati S; Boura JA; Yerkey MW; Glazier S; Grines CL; O'Neill WW
    Am J Cardiol; 2004 Jun; 93(12):1515-9. PubMed ID: 15194023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypertension is an independent risk factor for contrast nephropathy after percutaneous coronary intervention.
    Conen D; Buerkle G; Perruchoud AP; Buettner HJ; Mueller C
    Int J Cardiol; 2006 Jun; 110(2):237-41. PubMed ID: 16298441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.